Skip to main content
NCBI home page
Journal of Cellular and Molecular Medicine logoLink to Journal of Cellular and Molecular Medicine
. 2007 May 1;10(2):389–406. doi: 10.1111/j.1582-4934.2006.tb00407.x

Protein carbonylation, cellular dysfunction, and disease progression

Isabella Dalle-Donne a,*, Giancarlo Aldini b, Marina Carini b, Roberto Colombo a, Ranieri Rossi c, Aldo Milzani a
PMCID: PMC3933129  PMID: 16796807

Abstract

Carbonylation of proteins is an irreversible oxidative damage, often leading to a loss of protein function, which is considered a widespread indicator of severe oxidative damage and disease-derived protein dysfunction. Whereas moderately carbonylated proteins are degraded by the proteasomal system, heavily carbonylated proteins tend to form high-molecular-weight aggregates that are resistant to degradation and accumulate as damaged or unfolded proteins. Such aggregates of carbonylated proteins can inhibit proteasome activity. A large number of neurodegenerative diseases are directly associated with the accumulation of proteolysis-resistant aggregates of carbonylated proteins in tissues. Identification of specific carbonylated protein(s) functionally impaired and development of selective carbonyl blockers should lead to the definitive assessment of the causative, correlative or consequential role of protein carbonylation in disease onset and/or progression, possibly providing new therapeutic aproaches.

Keywords: Protein carbonyls, reactive oxygen species, reactive carbonyl species, protein unfolding/misfolding, proteasome, aggregation diseases

References

  • 1.Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol. 2000;279:L1005–28. doi: 10.1152/ajplung.2000.279.6.L1005. [DOI] [PubMed] [Google Scholar]
  • 2.Moldovan L, Moldovan NI. Oxygen free radicals and redox biology of organelles. Histochem Cell Biol. 2004;122:395–412. doi: 10.1007/s00418-004-0676-y. [DOI] [PubMed] [Google Scholar]
  • 3.Davies MJ, Fu S, Wang H, Dean RT. Stable markers of oxidant damage to proteins and their application in study of human disease. Free Radic Biol Med. 1999;27:1151–61. doi: 10.1016/s0891-5849(99)00206-3. [DOI] [PubMed] [Google Scholar]
  • 4.Cabiscol E, Ros J. Oxidative damage to proteins: Structural modifications and consequences in cell function. In: Dalle-Donne I, Scaloni A, Butterfield DA, editors. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Disease. Hoboken: John Wiley & Sons, Inc; 2006. pp. 399–471. [Google Scholar]
  • 5.Levine RL, Moskovitz J, Stadtman ER. Oxidation of methionine in proteins: roles in antioxidant defense and cellular regulation. IUBMB Life. 2000;50:301–7. doi: 10.1080/713803735. [DOI] [PubMed] [Google Scholar]
  • 6.Dalle-Donne I, Giustarini D, Colombo R, Milzani A, Rossi R. S-glutathionylation in human platelets by a thioldisulfide exchange-independent mechanism. Free Radic Biol Med. 2005;38:1501–10. doi: 10.1016/j.freeradbiomed.2005.02.019. [DOI] [PubMed] [Google Scholar]
  • 7.Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, Colombo R, Rossi R, Milzani A. Proteins as biological markers of oxidative/nitrosative stress in diseases. The contribution of redox-proteomics. Mass Spectrom Rev. 2005;24:55–99. doi: 10.1002/mas.20006. [DOI] [PubMed] [Google Scholar]
  • 8.Stadtman ER. Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences. Free Radic Biol Med. 1990;9:315–25. doi: 10.1016/0891-5849(90)90006-5. [DOI] [PubMed] [Google Scholar]
  • 9.Stadtman ER, Berlett BS. Fenton chemistry. Amino acid oxidation. J Biol Chem. 1991;266:17201–11. [PubMed] [Google Scholar]
  • 10.Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids amino acid residues in proteins. Amino Acids. 2003;25:207–18. doi: 10.1007/s00726-003-0011-2. [DOI] [PubMed] [Google Scholar]
  • 11.Stadtman ER, Levine RL. Chemical modification of proteins by reactive oxygen species. In: Dalle-Donne I, Scaloni A, Butterfield DA, editors. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Disease. Hoboken: John Wiley & Sons, Inc; 2006. pp. 3–23. [Google Scholar]
  • 12.Requena J, Chao CC, Stadtman ER. Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins. Proc Natl Acad Sci USA. 2001;98:69–74. doi: 10.1073/pnas.011526698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81–128. doi: 10.1016/0891-5849(91)90192-6. [DOI] [PubMed] [Google Scholar]
  • 14.Uchida K, Stadtman ER. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA. 1992;89:4544–8. doi: 10.1073/pnas.89.10.4544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Refsgaard HH, Tasi L, Stadtman ER. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA. 2000;97:611–6. doi: 10.1073/pnas.97.2.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends Mol Med. 2003;9:169–76. doi: 10.1016/s1471-4914(03)00031-5. [DOI] [PubMed] [Google Scholar]
  • 17.Butterfield DA, Castegna A. Proteomic analysis of oxidatively modified proteins in Alzheimer's disease brain: insights into neurodegeneration. Cell Mol Biol. 2003;49:747–51. [PubMed] [Google Scholar]
  • 18.Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52:601–23. doi: 10.1373/clinchem.2005.061408. [DOI] [PubMed] [Google Scholar]
  • 19.Levine RL, Stadtman ER. Carbonylated proteins and their implication in physiology and pathology. In: Dalle-Donne I, Scaloni A, Butterfield DA, editors. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Disease. Hoboken: John Wiley & Sons, Inc; 2006. pp. 563–603. [Google Scholar]
  • 20.Jana CK, Das N, Sohal RS. Specificity of age-related carbonylation of plasma proteins in the mouse and rat. Arch Biochem Biophys. 2002;397:433–9. doi: 10.1006/abbi.2001.2690. [DOI] [PubMed] [Google Scholar]
  • 21.Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. Oxidative modifications and aggregation of Cu/Zn superoxide dismutase associated with Alzheimer's and Parkinson's disease. J Biol Chem. 2005;280:11648–55. doi: 10.1074/jbc.M414327200. [DOI] [PubMed] [Google Scholar]
  • 22.Cabiscol E, Piulats E, Echave P, Herrero E, Ros J. Oxidative stress promotes specific protein damage in Saccharomyces cerevisiae. J Biol Chem. 2000;275:27393–8. doi: 10.1074/jbc.M003140200. [DOI] [PubMed] [Google Scholar]
  • 23.Yan L-J, Levine RL, Sohal RS. Oxidative damage during aging targets mitochondrial aconitase. Proc Natl Acad Sci. USA. 1997;94:11168–72. doi: 10.1073/pnas.94.21.11168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Yan L-J, Sohal RS. Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. Proc Natl Acad Sci USA. 1998;95:12896–901. doi: 10.1073/pnas.95.22.12896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Das N, Levine RL, Orr WC, Sohal RS. Selectivity of protein oxidative damage during aging in Drosophila melanogaster. Biochem J. 2001;360:209–16. doi: 10.1042/0264-6021:3600209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Yan L-J, Levine RL, Sohal RS. Effects of aging and hyperoxia on oxidative damage to cytochrome C in the housefly, Musca domestica. Free Radic Biol Med. 2000;29:90–7. doi: 10.1016/s0891-5849(00)00323-3. [DOI] [PubMed] [Google Scholar]
  • 27.Stadtman ER. Protein oxidation and aging. Science. 1992;257:1220–4. doi: 10.1126/science.1355616. [DOI] [PubMed] [Google Scholar]
  • 28.Merker K, Grune T. Proteolysis of oxidized proteins and cellular senescence. Exp Gerontol. 2000;35:779–86. doi: 10.1016/s0531-5565(00)00140-6. [DOI] [PubMed] [Google Scholar]
  • 29.Ghezzo-Schöneich E, Esch SW, Sharov VS, Schöneich C. Biological aging does not lead to the accumulation of oxidized Cu, Zn-superoxide dismutase in the liver of F344 rats. Free Radic Biol Med. 2001;30:858–64. doi: 10.1016/s0891-5849(01)00473-7. [DOI] [PubMed] [Google Scholar]
  • 30.Reverter-Branchat G, Cabiscol E, Tamarit J, Ros J. Oxidative damage to specific proteins in replicative and chronological-aged Saccharomyces cerevisiae: common targets and prevention by calorie restriction. J Biol Chem. 2004;279:31983–9. doi: 10.1074/jbc.M404849200. [DOI] [PubMed] [Google Scholar]
  • 31.Aguilaniu H, Gustafsson L, Rigoulet M, Nyström T. Asymmetric inheritance of oxidatively damaged proteins during cytokinesis. Science. 2003;299:1751–3. doi: 10.1126/science.1080418. [DOI] [PubMed] [Google Scholar]
  • 32.Dukan S, Farewell A, Ballesteros M, Taddei F, Radman M, Nyström T. Protein oxidation in response to increased transcriptional or translational errors. Proc Natl Acad Sci USA. 2000;97:5746–9. doi: 10.1073/pnas.100422497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ballesteros M, Fredriksson A, Henriksson J, Nyström T. Bacterial senescence: protein oxidation in non-proliferating cells is dictated by the accuracy of the ribosomes. EMBO J. 2001;20:5280–9. doi: 10.1093/emboj/20.18.5280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Fredriksson A, Ballesteros M, Dukan S, Nyström T. Defense against protein carbonylation by DnaK/DnaJ and proteases of the heat shock regulon. J Bacteriol. 2005;187:4207–13. doi: 10.1128/JB.187.12.4207-4213.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.England K, Cotter T. Identification of carbonylated proteins by MALDI-TOF mass spectroscopy reveals susceptibility of ER. Biochem Biophys Res Commun. 2004;320:123–30. doi: 10.1016/j.bbrc.2004.05.144. [DOI] [PubMed] [Google Scholar]
  • 36.Rabek JP, Boylston WH, Papaconstantinou J. Carbonylation of ER chaperone proteins in aged mouse liver. Biochem Biophys Res Commun. 2003;305:566–72. doi: 10.1016/s0006-291x(03)00826-x. [DOI] [PubMed] [Google Scholar]
  • 37.Dalle-Donne I, Rossi R, Giustarini D, Gagliano N, Lusini L, Milzani A, DiSimplicio P, Colombo R. Actin carbonylation: from a simple marker of protein oxidation to relevant signs of severe functional impairment. Free Radic Biol Med. 2001;31:1075–83. doi: 10.1016/s0891-5849(01)00690-6. [DOI] [PubMed] [Google Scholar]
  • 38.Aldini G, Dalle-Donne I, Vistoli G, Maffei Facino R, Carini M. Covalent modification of actin by 4-hydroxy-trans-2-nonenal (HNE): LC-ESI-MS/MS evidence for Cys374 Michael adduction. J Mass Spectrom. 2005;40:946–54. doi: 10.1002/jms.872. [DOI] [PubMed] [Google Scholar]
  • 39.Neely MD, Sidell KR, Graham DG, Montine TJ. The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J Neurochem. 1999;72:2323–33. doi: 10.1046/j.1471-4159.1999.0722323.x. [DOI] [PubMed] [Google Scholar]
  • 40.Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, Szweda LI, Kaminiski MA, Avila J, Price DL, Cleveland DW, Sayre LM, Perry G. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem. 2002;277:4644–8. doi: 10.1074/jbc.M110913200. [DOI] [PubMed] [Google Scholar]
  • 41.Oh-Ishi M, Ueno T, Maeda T. Proteomic method detects oxidatively induced protein carbonyls in muscles of a diabetes model Otsuka Long-Evans Tokushima Fatty (OLETF) rat. Free Radic Biol Med. 2003;34:11–22. doi: 10.1016/s0891-5849(02)01239-x. [DOI] [PubMed] [Google Scholar]
  • 42.O'Reilly PJ, Hickman-Davis JM, Davis IC, Matalon S. Hyperoxia impairs antibacterial function of macrophages through effects on actin. Am J Respir Cell Mol Biol. 2003;28:443–50. doi: 10.1165/rcmb.2002-0153OC. [DOI] [PubMed] [Google Scholar]
  • 43.Barreiro E, Gea J, Di Falco M, Kriazhev L, James S, Hussain SN. Protein carbonyl formation in the diaphragm. Am J Respir Cell Mol Biol. 2005;32:9–17. doi: 10.1165/rcmb.2004-0021OC. [DOI] [PubMed] [Google Scholar]
  • 44.Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, Butterfield DA. Proteomic identification of proteins oxidized by Aβ(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res. 2005;1044:206–15. doi: 10.1016/j.brainres.2005.02.086. [DOI] [PubMed] [Google Scholar]
  • 45.Banan A, Zhang Y, Losurdo J, Keshavarzian A. Carbonylation and disassembly of the F-actin cytoskeleton in oxidant induced barrier dysfunction and its prevention by epidermal growth factor and transforming growth factor alpha in a human colonic cell line. Gut. 2000;46:830–7. doi: 10.1136/gut.46.6.830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Keshavarzian A, Banan A, Farhadi A, Komanduri S, Mutlu E, Zhang Y, Fields JZ. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatroy bowel disease. Gut. 2003;52:720–8. doi: 10.1136/gut.52.5.720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Powell SR, Gurzenda EM, Wahezi SE. Actin in oxidized during myocardial ischemia. Free Radic Biol Med. 2001;30:1171–6. doi: 10.1016/s0891-5849(01)00514-7. [DOI] [PubMed] [Google Scholar]
  • 48.Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. Neuroscience. 2001;103:373–83. doi: 10.1016/s0306-4522(00)00580-7. [DOI] [PubMed] [Google Scholar]
  • 49.England K, O'Driscoll C, Cotter TG. Carbonylation of glycolytic proteins is a key response to drug-induced oxidative stress and apoptosis. Cell Death Differ. 2004;11:252–60. doi: 10.1038/sj.cdd.4401338. [DOI] [PubMed] [Google Scholar]
  • 50.Nguyen AT, Donaldson RP. Metal-catalyzed oxidation induces carbonylation of peroxisomal proteins and loss of enzymatic activites. Arch Biochem Biophys. 2005;439:25–31. doi: 10.1016/j.abb.2005.04.018. [DOI] [PubMed] [Google Scholar]
  • 51.Siems WG, Hapner SJ, van Kujk FJGM. 4-Hydroxynonenal inhibits Na+--K+-ATPase. Free Radic Biol Med. 1996;20:215–23. doi: 10.1016/0891-5849(95)02041-1. [DOI] [PubMed] [Google Scholar]
  • 52.Chen J, Bertrand AH, Yu BP. Inhibition of mitochondrial adenine nucleotide translocator by lipid peroxidation products. Free Radic Biol Med. 1995;19:583–90. doi: 10.1016/0891-5849(95)00066-7. [DOI] [PubMed] [Google Scholar]
  • 53.Chen J, Henderson GI, Freeman GL. Role of 4-hydroxynonenal in modification of cytochrome c oxidase in ischemia/reperfused rat heart. J Mol Cell Cardiol. 2001;33:1919–27. doi: 10.1006/jmcc.2001.1454. [DOI] [PubMed] [Google Scholar]
  • 54.Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ1-42. J Neurochem. 2001;78:413–6. doi: 10.1046/j.1471-4159.2001.00451.x. [DOI] [PubMed] [Google Scholar]
  • 55.Choksi KB, Boylston WH, Rabek JP, Widger WR, Papaconstantinou J. Oxidatively damaged proteins of heart mitochondrial electron transport comlexes. Biochim Biophys Acta. 2004;1968:95–101. doi: 10.1016/j.bbadis.2003.11.007. [DOI] [PubMed] [Google Scholar]
  • 56.Wen JJ, Garg N. Oxidative modification of mitochondrial respiratory complexes in response to the stress of Trypanosoma cruzi infection. Free Radic Biol Med. 2004;37:2072–81. doi: 10.1016/j.freeradbiomed.2004.09.011. [DOI] [PubMed] [Google Scholar]
  • 57.Yarian CS, Rebrin I, Sohal RS. Aconitase and ATP synthase are targets of malondialdehyde modification and undergo an age-related decrease in activity in mouse heart mitochondria. Biochem Biophys Res Commun. 2005;330:151–6. doi: 10.1016/j.bbrc.2005.02.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Shamoto-Nagai M, Maruyama W, Kato Y, Isobe K, Tanaka M, Naoi M, Osawa T. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res. 2003;74:589–97. doi: 10.1002/jnr.10777. [DOI] [PubMed] [Google Scholar]
  • 59.Dawson TM, Dawson VL. Molecular pathways of neurodegneration in Parkinson's disease. Science. 2003;302:819–22. doi: 10.1126/science.1087753. [DOI] [PubMed] [Google Scholar]
  • 60.Wilson MR, Easterbrook Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci. 2000;25:95–8. doi: 10.1016/s0968-0004(99)01534-0. [DOI] [PubMed] [Google Scholar]
  • 61.Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY, Arnold SM. The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol. 2002;3:411–21. doi: 10.1038/nrm829. [DOI] [PubMed] [Google Scholar]
  • 62.Horwich A. Protein aggregation in disease: a role for folding intermediates forming specific multimeric ineractions. J Clin Invest. 2002;110:1221–32. doi: 10.1172/JCI16781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Dobson CM. Protein folding and misfolding. Nature. 2003;426:884–90. doi: 10.1038/nature02261. [DOI] [PubMed] [Google Scholar]
  • 64.Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292:1552–5. doi: 10.1126/science.292.5521.1552. [DOI] [PubMed] [Google Scholar]
  • 65.Sherman M, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 2001;29:15–32. doi: 10.1016/s0896-6273(01)00177-5. [DOI] [PubMed] [Google Scholar]
  • 66.Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nature Med. 2004;10:S2–9. doi: 10.1038/nm1067. [DOI] [PubMed] [Google Scholar]
  • 67.Barral JM, Broadley SA, Schaffar G, Hartl FU. Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol. 2004;15:17–29. doi: 10.1016/j.semcdb.2003.12.010. [DOI] [PubMed] [Google Scholar]
  • 68.Bieschke J, Weber P, Sarafoff N, Beekes M, Giese A, Kretzshmar H. Autocatalytic self-propgation of misfolded prion protein. Proc Natl Acad Sci USA. 2004;101:12207–11. doi: 10.1073/pnas.0404650101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Berke SJ, Paulson HL. Protein aggregation and the ubiquitin proteasome pathway: gaining the upper hand on neurodegeneration. Curr Opin Genet Dev. 2003;13:253–61. doi: 10.1016/s0959-437x(03)00053-4. [DOI] [PubMed] [Google Scholar]
  • 70.Grune T, Jung T, Merker K, Davies KJ. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and aggresomes'during oxidative stress, aging, and disease. Int Biochem Cell Biol. 2004;36:2519–30. doi: 10.1016/j.biocel.2004.04.020. [DOI] [PubMed] [Google Scholar]
  • 71.Voss P, Grune T. Degradation and accumulation of oxidized proteins in age related diseases. In: Dalle-Donne I, Scaloni A, Butterfield DA, editors. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Disease. Hoboken: John Wiley & Sons, Inc; 2006. pp. 527–562. [Google Scholar]
  • 72.Nyström T. Role of oxidative carbonylation in protein quality control and sensecence. EMBO J. 2005;24:1311–7. doi: 10.1038/sj.emboj.7600599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Guo B, Phillips JD, Yu Y, Leibold EA. Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome. J Biol Chem. 1995;270:21645–51. doi: 10.1074/jbc.270.37.21645. [DOI] [PubMed] [Google Scholar]
  • 74.Iwai K, Klausner RD, Rouault TA. Requirements for iron-regulated degradation of the RNA binding protein, iron regulatory protein 2. EMBO J. 1995;14:5350–7. doi: 10.1002/j.1460-2075.1995.tb00219.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Iwai K, Drake SK, Wehr NB, Weissman AM, La Vaute T, Minato N, Klausner RD, Levine RL, Rouault TA. Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: implications for degradation of oxidized proteins. Proc Natl Acad Sci USA. 1998;95:4924–8. doi: 10.1073/pnas.95.9.4924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Shringarpure R, Davies KJ. Protein turnover by the proteasome in aging and disease. Free Radic Biol Med. 2002;32:1084–9. doi: 10.1016/s0891-5849(02)00824-9. [DOI] [PubMed] [Google Scholar]
  • 77.Shringarpure R, Grune T, Mehlhase J, Davies KJA. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem. 2003;278:311–8. doi: 10.1074/jbc.M206279200. [DOI] [PubMed] [Google Scholar]
  • 78.Grune T, Merker K, Jung T, Sitte N, Davies KJ. Protein oxidation and degradation during postmitotic senescence. Free Radic Biol Med. 2005;39:1208–15. doi: 10.1016/j.freeradbiomed.2005.06.009. [DOI] [PubMed] [Google Scholar]
  • 79.Powell SR, Wang P, Divald A, Teichberg S, Haridas V, McCloskey TW, Davies KJ, Katzeff H. Aggregates of oxidized proteins (lipofuscin) induce apoptosis through proteasome inhibition and dysregulation of proapoptotic proteins. Free Radic Biol Med. 2005;38:1093–101. doi: 10.1016/j.freeradbiomed.2005.01.003. [DOI] [PubMed] [Google Scholar]
  • 80.Ding Q, Keller JN. Proteasomes and proteasome inhibition in the central nervous system. Free Radic Biol Med. 2001;31:574–84. doi: 10.1016/s0891-5849(01)00635-9. [DOI] [PubMed] [Google Scholar]
  • 81.Lee M, Hyun DH, Jenner P, Halliwell B. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitirc oxide production. J Neurochem. 2001;78:32–41. doi: 10.1046/j.1471-4159.2001.00416.x. [DOI] [PubMed] [Google Scholar]
  • 82.Hyun DH, Lee M, Halliwell B, Jenner P. Proteasomal inhibition induces the formation of aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem. 2003;86:363–73. doi: 10.1046/j.1471-4159.2003.01841.x. [DOI] [PubMed] [Google Scholar]
  • 83.Hyun DH, Gray DA, Halliwell B, Jenner P. Interfernce with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseases. J Neurochem. 2004;90:422–30. doi: 10.1111/j.1471-4159.2004.02493.x. [DOI] [PubMed] [Google Scholar]
  • 84.Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem. 2000;75:436–9. doi: 10.1046/j.1471-4159.2000.0750436.x. [DOI] [PubMed] [Google Scholar]
  • 85.Chung KK, Dawson VL, Dawson TM. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 2001;24:S7–14. doi: 10.1016/s0166-2236(00)01998-6. [DOI] [PubMed] [Google Scholar]
  • 86.Giasson BI, Ischiropoulos H, Lee VM, Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med. 2002;32:1264–75. doi: 10.1016/s0891-5849(02)00804-3. [DOI] [PubMed] [Google Scholar]
  • 87.McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci. 2001;2:589–94. doi: 10.1038/35086067. [DOI] [PubMed] [Google Scholar]
  • 88.Fortun J, Li J, Go J, Fenstermaker A, Fletcher BS, Notterpek L. Impaired proteasome activity and accumulation of ubiquitinated substrates in a hereditary neuropathy model. J Neurochem. 2005;92:1531–41. doi: 10.1111/j.1471-4159.2004.02987.x. [DOI] [PubMed] [Google Scholar]
  • 89.Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003;53:S26–38. doi: 10.1002/ana.10483. [DOI] [PubMed] [Google Scholar]
  • 90.Shringarpure R, Grune T, Sitte N, Davies KJA. 4-Hydroxynonenal-modified amyloid-β peptide inhibits the proteasome: possible importance in Alzheimer's disease. Cell Mol Life Sci. 2000;57:1802–8. doi: 10.1007/PL00000660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA. 1996;93:2696–701. doi: 10.1073/pnas.93.7.2696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, Kasarskis E, Mattson MP. Protein modification by the lipid peroxidation product 4-hydrox-ynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol. 1998;44:819–24. doi: 10.1002/ana.410440518. [DOI] [PubMed] [Google Scholar]
  • 93.Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerbrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Nerol. 1998;44:696–9. doi: 10.1002/ana.410440419. [DOI] [PubMed] [Google Scholar]
  • 94.Friguet B, Szweda LI. Inhibition of multicatalytic proteinase (proteasome) by 4-hydroxynonenal cross-linked protein. FEBS Lett. 1997;405:21–5. doi: 10.1016/s0014-5793(97)00148-8. [DOI] [PubMed] [Google Scholar]
  • 95.Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tananka K, Uchida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. J Biol Chem. 1999;274:23787–93. doi: 10.1074/jbc.274.34.23787. [DOI] [PubMed] [Google Scholar]
  • 96.Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B, Szweda LI. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem. 2001;276:30057–63. doi: 10.1074/jbc.M100142200. [DOI] [PubMed] [Google Scholar]
  • 97.Powell SR, Wang P, Katzeff H, Shringarpure R, Teoh C, Khaliulin I, Das DK, Davies KJ, Schwalb H. Oxidized and ubiqutinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid Redox Signal. 2005;7:538–46. doi: 10.1089/ars.2005.7.538. [DOI] [PubMed] [Google Scholar]
  • 98.Divald A, Powell SR. Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic Biol Med. 2006;40:156–64. doi: 10.1016/j.freeradbiomed.2005.09.022. [DOI] [PubMed] [Google Scholar]
  • 99.Ishii T, Sakurai T, Usami H, Uchida K. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S proteasome. Biochemistry. 2005;44:13893–901. doi: 10.1021/bi051336u. [DOI] [PubMed] [Google Scholar]
  • 100.Cahuana GM, Tejedo JR, Jimenez J, Ramirez R, Sobrino F, Bedoya FJ. Involvement of advanced lipooxidation end products (ALEs) and protein oxidation in the apoptotic actions of nitric oxide in insulin secreting RINm5F cells. Biochem Pharmacol. 2003;66:1963–71. doi: 10.1016/j.bcp.2003.07.004. [DOI] [PubMed] [Google Scholar]
  • 101.Cahuana GM, Tejedo JR, Jimenez J, Ramirez R, Sobrino F, Bedoya FJ. Nitric oxide-induced carbonylation of Bcl-2, GAPDH and ANT precedes apoptotic events in insulin-secreting RINm5F cells. Exp Cell Res. 2004;293:22–30. doi: 10.1016/j.yexcr.2003.10.004. [DOI] [PubMed] [Google Scholar]
  • 102.Keller JN, Huang FF, Dimayuga ER, Maragos WF. Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic Biol Med. 2000;29:1037–42. doi: 10.1016/s0891-5849(00)00412-3. [DOI] [PubMed] [Google Scholar]
  • 103.Beal MF. Oxidatively modified proteins in aging and disease. Free Radic Biol Med. 2002;32:797–803. doi: 10.1016/s0891-5849(02)00780-3. [DOI] [PubMed] [Google Scholar]
  • 104.Sohal RS. Role of oxidative stress protein oxidation in the aging process. Free Radic Biol Med. 2002;33:37–44. doi: 10.1016/s0891-5849(02)00856-0. [DOI] [PubMed] [Google Scholar]
  • 105.Sohal RS, Mockett RJ, Orr WC. Mechanisms of aging: an appraisal of the oxidative stress hypothesis. Free Radic Biol Med. 2002;33:575–86. doi: 10.1016/s0891-5849(02)00886-9. [DOI] [PubMed] [Google Scholar]
  • 106.Renke J, Popadiuk S, Korzon M, Bugajczyk B, Wozniak M. Protein carbonyl groups content as a useful clinical marker of antioxidant barrier impairment in plasma of children with juvenile chronic arthritis. Free Radic Biol Med. 2000;29:101–4. doi: 10.1016/s0891-5849(00)00288-4. [DOI] [PubMed] [Google Scholar]
  • 107.Buss IH, Darlow BA, Winterbourn CC. Elevated protein carbonyls and lipid peroxidation products correlating with myeloperoxidase in tracheal aspirates from premature infants. Pediatr Res. 2000;47:640–5. doi: 10.1203/00006450-200005000-00014. [DOI] [PubMed] [Google Scholar]
  • 108.Winterbourn CC, Buss IH, Chan TP, Plank LD, Clark MA, Windsor JA. Protein carbonyl measurements show evidence of early oxidative stress in critically ill patient. Crit Care Med. 2000;28:143–9. doi: 10.1097/00003246-200001000-00024. [DOI] [PubMed] [Google Scholar]
  • 109.Winterbourn CC, Bonham MJ, Buss H, Abu-Zidan FM, Windsor JA. Elevated protein carbonyls as plasma markers of oxidative stress in acute pancreatitis. Pancreatology. 2003;3:375–82. doi: 10.1159/000073652. [DOI] [PubMed] [Google Scholar]
  • 110.Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005;64:1152–6. doi: 10.1212/01.WNL.0000156156.13641.BA. [DOI] [PubMed] [Google Scholar]
  • 111.Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type 1 diabetes mellitus in children and adolescents. Diabetes Care. 1998;21:1736–42. doi: 10.2337/diacare.21.10.1736. [DOI] [PubMed] [Google Scholar]
  • 112.Dominguez C, Gussinye M, Martin P, Carrascosa A. Antioxidant status and free radical-mediated oxidative damage in young type 1 diabetic patients. Diabetes Care. 1999;22:871–3. [Google Scholar]
  • 113.Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med. 2003;34:1563–74. doi: 10.1016/s0891-5849(03)00185-0. [DOI] [PubMed] [Google Scholar]
  • 114.Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1–9. doi: 10.2337/diabetes.48.1.1. [DOI] [PubMed] [Google Scholar]
  • 115.Baynes JW, Thorpe SR. p. 16. Glycoxidation and lipoxidation in atherogenesis. [DOI] [PubMed]
  • 116.Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem. 2003;278:42012–9. doi: 10.1074/jbc.M304292200. [DOI] [PubMed] [Google Scholar]
  • 117.Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys. 2003;419:41–9. doi: 10.1016/j.abb.2003.08.021. [DOI] [PubMed] [Google Scholar]
  • 118.Miyata T, Van-Ypersele-de-Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int. 1999;55:389–99. doi: 10.1046/j.1523-1755.1999.00302.x. [DOI] [PubMed] [Google Scholar]
  • 119.Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37–57. doi: 10.1016/s0074-7742(02)50072-6. [DOI] [PubMed] [Google Scholar]
  • 120.Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405–12. doi: 10.2337/diab.40.4.405. [DOI] [PubMed] [Google Scholar]
  • 121.Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res. 2003;37:471–80. doi: 10.1080/1071576031000083161. [DOI] [PubMed] [Google Scholar]
  • 122.Raabe HM, Hopner JH, Notbohm H, Sinnecker GH, Kruse K, Muller PK. Biochemical and biophysical alterations of the 7S and NC1 domain of collagen IV from human diabetic kidneys. Diabetologia. 1998;41:1073–9. doi: 10.1007/s001250051032. [DOI] [PubMed] [Google Scholar]
  • 123.Mott JD, Khalifah RG, Nagase H, Shield CF, 3rd, Hudson J, Hudson BG. Glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int. 1997;52:1302–2. doi: 10.1038/ki.1997.455. [DOI] [PubMed] [Google Scholar]
  • 124.Miyata T, Van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K. Angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002;13:2478–87. doi: 10.1097/01.asn.0000032418.67267.f2. [DOI] [PubMed] [Google Scholar]
  • 125.Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes. 2003;52:2110–20. doi: 10.2337/diabetes.52.8.2110. [DOI] [PubMed] [Google Scholar]
  • 126.Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets. 2005;6:453–74. doi: 10.2174/1389450054021873. [DOI] [PubMed] [Google Scholar]
  • 127.Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. Am J Ther. 2005;12:562–72. doi: 10.1097/01.mjt.0000178769.52610.69. [DOI] [PubMed] [Google Scholar]
  • 128.Wihler C, Schafer S, Schmid K, Deemer EK, Munch G, Bleich M, Busch AE, Dingermann T, Somoza V, Baynes JW, Huber J. Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia. 2005;48:1645–53. doi: 10.1007/s00125-005-1837-9. [DOI] [PubMed] [Google Scholar]
  • 129.Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys. 2003;419:31–40. doi: 10.1016/j.abb.2003.08.013. [DOI] [PubMed] [Google Scholar]
  • 130.Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SM, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004;53:1813–23. doi: 10.2337/diabetes.53.7.1813. [DOI] [PubMed] [Google Scholar]
  • 131.Stadler K, Jenei V, Somogyi A, Jakus J. Beneficial effects of aminoguanidine on the cardiovascular system of dibetic rats. Diabetes Metab Res Rev. 2005;21:189–96. doi: 10.1002/dmrr.501. [DOI] [PubMed] [Google Scholar]
  • 132.Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW. The AGE inhibitor pyridoxamine inhibits lipemia anddevelopment of renal and vascular disease in Zucker obese rats. Kidney Int. 2003;63:2123–33. doi: 10.1046/j.1523-1755.2003.00027.x. [DOI] [PubMed] [Google Scholar]
  • 133.Voziyan PA, Hudson BG. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann NY Acad Sci. 2005;1043:807–16. doi: 10.1196/annals.1333.093. [DOI] [PubMed] [Google Scholar]
  • 134.Hipkiss AR, Brownson C. A possible new role for the anti-ageing peptide carnosine. Cell Mol Life Sci. 2000;57:747–53. doi: 10.1007/s000180050039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Dalle-Donne I, Scaloni A, Butterfield DA. Redox proteomics: from Protein modifications to cellular dysfunction and disease. Hoboken: John Wiley & Sons, Inc; 2006. [DOI] [PubMed] [Google Scholar]
  • 136.Moreau R, Heath SH, Doneanu CE, Lindsay JG, Hagen TM. Age-related increase in 4-hydroxynonenal adduction to rat heart α-ketoglutarate dehydrogenase does not cause loss of its catalytic activity. Antioxid Redox Signal. 2003;5:517–27. doi: 10.1089/152308603770310167. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cellular and Molecular Medicine are provided here courtesy of Blackwell Publishing

RESOURCES